Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Q8VM
|
|||
Former ID |
DNCL002930
|
|||
Drug Name |
TT-401
|
|||
Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1], [2] | |
Company |
Transition Therapeutics
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon receptor (GCGR) | Target Info | Agonist | [2] |
Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Modulator | [3] | |
KEGG Pathway | cAMP signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Insulin secretion | ||||
Glucagon signaling pathway | ||||
Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
Glucagon signaling in metabolic regulation | ||||
G alpha (q) signalling events | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
Gastrin-CREB signalling pathway via PKC and MAPK |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035378) | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration. Am J Ophthalmol. 2013 Dec;156(6):1176-83. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.